B+
Bull case
25%
Probability
Target price
$275.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
JAZZ
Jazz PublicBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 revenue rose 16% year over year to $1.21 billion, supported by Xywav, Epidiolex, Zepzelca and Modeyso; Jazz raised 2026 revenue guidance to $4.60–$4.75 billion from $4.25–$4.50 billion. Ziihera's approved first-line GEA regimens offer an additional commercial opportunity.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Chief commercial officer succession could disrupt launch execution, although the filing reports no such disruption. [#8-K-2026-10-09] https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/jazz-20261006.htm
Momentum
45
Value
65
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $220.00 · Bull $275.00 · Bear $160.00Analysis 2026-10-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $297.57
Why
Momentum45 · Δ7d -21.2
Value65 · Δ7d -0.3
Sentiment58 · Δ7d -1.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Chief commercial officer succession could disrupt launch execution, although the filing reports no such disruption. [#8-K-2026-10-09] https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/jazz-20261006.htm
- • June 30 long-term debt principal of $4.4 billion versus $2.2 billion of cash, equivalents and investments leaves capital-allocation sensitivity. [#SEC-8K-2026-08-03] https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm
- • Positive Ziihera clinical news and approval are already public, while uptake and reimbursement remain unproven.
Catalyst clock
2026-12-31
Detailed HERIZON-GEA-01 survival results
Lead driver: Value · See fundamentals
Momentum
45
8% active weight
Current posture
7d trendSoftening
Δ7d
-21.2
Δ21d
-22.0
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.1
Sentiment
58
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.9
Δ21d
-13.4
Why this grade
Composite grade B. Momentum 44.6 / Value 65.1 / Sentiment 57.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$13.89B
Beta
0.26
Shares Out
64.91M
P/E (TTM) · Derived
-36.6
P/S (TTM)
2.55
P/FCF (TTM)
8.55
Rev YoY
+15.5%
EPS YoY
-123.7%
Gross Margin
+73.6%
Op Margin
+20.8%
Net Debt
$2.99B
Current Ratio
1.78
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data